Heart disease is the leading cause of death in the US. Following an acute myocardial infarction, a fibrous, noncontractile scar develops, and results in congestive heart failure in more than 500,000 patients in the US each year. Muscle regeneration and the induction of new vascular growth to treat ischemic disorders of the heart can have significant therapeutic implications. Early studies in patients with chronic ischemic systolic left ventricular dysfunction (SLVD) using skeletal myoblasts or bone marrow-derived cells report improvement in left ventricular ejection function (LVEF) and clinical status, without notable safety issues. Nonetheless, the efficacy of cell transfer for cardiovascular disease is not established, in part due to a lack of control over cell retention, survival, and function following delivery. We studied the use of biocompatible hydrogels polymerizable in situ as a cell delivery vehicle, to improve cell retention, survival, and function following delivery into the ischemic myocardium. The study was conducted using human bone marrow-derived mesenchymal stem cells and fibrin glue, but the methods are applicable to any human stem cells (adult or embryonic) and a wide range of hydrogels. We first evaluated the utility of several commercially available percutaneous catheters for delivery of viscous cell/hydrogel suspensions. Next we characterized the polymerization kinetics of fibrin glue solutions to define the ranges of concentrations compatible with catheter delivery. We then demonstrate the in vivo effectiveness of this preparation and its ability to increase cell retention and survival in a nude rat model of myocardial infarction.
INTRODUCTION
profiles of cell injection techniques (15) . However, the efficacy of cell-based procedures has not been well established, in part due to a lack of control over cell reten-Congestive heart failure (CHF) is an enormous health problem in the US, affecting nearly 5 million people (0.5 tion, survival, and function following delivery.
The key limitation of all existing modalities of cell million newly diagnosed/year) and imposing a significant burden on those afflicted (12-15 million office vis-delivery is the massive cell loss that occurs within a very short time and, irrespective of cell type or formulation, its, 6.5 million hospital days, and almost 0.3 million deaths/year) that is surely to increase as the population delivery technique and disease state. Estimates for acute retention vary depending upon route of delivery but are ages (7) . While cardiac transplantation remains the definitive treatment for end-stage heart failure, it is seri-uniformly poor (5, 9) . For instance, in an elegant study utilizing radio-labeled bone marrow mononuclear cells ously limited by a scarcity of available donor organs. Alternative approaches such as cell-based therapies have (6) , only 11 ± 3% of cells remained in the heart just 90 min after intramyocardial injection. Retention rates for therefore garnered much attention in recent years. Early cell therapy studies utilized skeletal myoblasts (12) or intracoronary (2.6 ± 0.3%) and retrograde venous delivery (3.2 ± 1.0%) were even lower. All three methods bone marrow-derived stem cells (11) with or without concomitant revascularization. These studies demon-were associated with rapid redistribution of the cells delivered into the heart to the lungs, liver, spleen, and strated modest gains in left ventricular ejection fraction (LVEF) and clinical status, along with excellent safety other organs throughout the body. Postulated mecha-298 MARTENS ET AL.
nisms for poor retention include inadvertent intravascu-that in turn limits the maximum viscosity of the injectate. Second, because current catheters employ a single lar delivery to coronary veins and venules, rapid interstitial clearance by lymphatics, and direct leakage of cell injection lumen, the fibrin glue components must be mixed prior to injection, resulting in a time-dependant suspension once the needle is removed.
In addition, the local environment presents an untena-increase in viscosity of cell/hydrogel suspension. A successful formulation must therefore polymerize quickly ble milieu for freshly implanted cells following both acute (inflammation) and chronic (fibrosis) myocardial enough to improve cell retention, yet slowly enough to allow adequate time for injection site selection, catheter infarction (14) . The infarct bed is poorly oxygenated, contains dead and apoptotic cells, and has a progres-positioning, and delivery. In this article we first assess the utility of several sively increasing stiffness, a combination of features that does not support the viability and well-being of im-commercially available percutaneous catheters using standards of solutions with known viscosity to determine planted cells. This additional limitation of delivering "naked" cells has prompted research towards multiple a working limit for this parameter. Next we characterize the polymerization kinetics of different fibrin glue solu-other modalities for cell delivery-from the use of biomaterials as cell delivery vehicles (4) to engineering a tions to define the ranges of parameters compatible with catheter delivery. We then demonstrate the in vitro and contractile cardiac "patch" containing the repair cells (10) .
in vivo effectiveness of this preparation, and its ability to increase cell retention and prevent redistribution of Intramyocardial in situ polymerization of polymers in form of a hydrogel represents one possible solution to delivered product in an animal model of myocardial infarction. address both leakage and clearance-mediated cell loss, and the need for "conditioning" of the immediate cell MATERIALS AND METHODS environment. There are a number of biocompatible hy-Viscosity Limit of Clinically Available Catheters drogels, polymerizing in response to chemical, thermal, or optical triggers, including fibrin (1), alginate (8), and A system for rheological measurements with constant polyethylene glycol-based systems (2) . Fibrin glue is a fluid pressure was established, whereby a solution was hydrogel widely used in surgery, cell culture, and tissue pushed through each of the catheters tested at a constant engineering that consists of a two-component system. flow velocity. Dextran solutions of known viscosity Fibrinogen monomers (component A) are dissolved in (Sigma, at 5%, 10%, 20%, 25% w/v) were passed through a liquid carrier such as saline. Exposure of fibrinogen catheters and the ease with which the solution flowed monomers to thrombin (component B) results in converwas characterized as "easily delivered" (+), "low flow" sion of fibrinogen to fibrin, which polymerizes to form (LF), or "no flow" (NF). Viscosities of each dextran soa fibrin mesh, by mechanisms similar to those involved lution were then confirmed using an ARES-LS1 Rheomin normal clotting in vivo. Both autologous and recometer (TI Instruments), using cone-and-plate configurabinant off-the-shelf fibrin glue preparations are availtion with diameter of 5 cm, and angular displacement of able, and have seen extensive use as procoagulants dur-0.01 radians at 1 Hz. ing cardiac and other surgery. Additionally, preclinical Time-Dependent Viscosity Profiles literature supports an angiogenic role for fibrin glue following myocardial ischemia in rats, making this an at-Bovine fibrinogen (Sigma) was dissolved in PBS to tractive system for possible catheter-based cell therapy yield 1%, 2%, 5%, 10%, and 15% (w/v) solutions. Each of the heart (3). of these solutions was loaded into the cone-and-plate con-Cell delivery to the heart is being performed by surgifigured Ares-LS1 Rheometer (TA instruments). Thrombin cal and catheter-based (percutanous) methods. Catheter-(Sigma T6200) was reconstituted to a concentration of based cell delivery has several advantages over direct 100 U/ml. Diluted thrombin, 50 U/ml and 20 U/ml, was surgical injection: 1) lower procedure risk, 2) high pocombined with fibrinogen at a concentration of 2%, 5%, tential for integration into clinical practice, and 3) more or 10% w/v to initiate polymerization to fibrin glue. suitability for repeat applications compared to surgery.
Cell Viability in Fibrin For these reasons, the majority of current cardiac cell therapy trials employ a percutaneous delivery method, To obtain human mesenchymal stem cells (hMSCs), human bone marrow mononuclear cells (LONZA 2M-the most common type of which is endoventricular or transendocardial injection (13). 125) were plated in T75 flasks and cultured in DMEM (Gibco, #12430) with 10% FBS (Gibco, #26140). The However, the use of intramyocardial injection catheters also imposes significant design constraints on a cell/ adherent cells were expanded to the fourth passage for use in all subsequent experiments. hMSCs were encap-hydrogel preparation (Fig. 1) . First, the long internal lumen of the catheter imposes a high resistance to flow sulated in fibrin gels at a density of 4 × 10 6 cells/cm 3 . Fibrin gels were fabricated by combining 2% w/v fibrin-to injection. Aliquots of 500,000 labeled hMSCs were suspended either in 300 µl of PBS (n = 6) or a 300-ogen with 20 U/ml thrombin in a 96-well plate. At time points of 0.5, 24, and 72 h after gel fabrication, gels µl mixture of fibrin glue (2% w/v fibrinogen, 20 U/ml thrombin, n = 6) and immediately injected into the bor-were stained with LIVE/DEAD Invitrogen L-3224 and digital images obtained from a fluorescent microscope.
der zone in two divided injections of 150 µl each. Ninety minutes after cell injection, the rats were euthan-Images were then analyzed in Matlab using codes written to allow automated unbiased counting of red (dead) ized and the heart, lungs, liver, kidneys, and spleen were recovered. Tissue specimens were dehydrated and sent and green (live) hMSCs.
to Biopal for neutron beam bombardment and quantifi-Scanning Electron Microscopy cation according to the manufacturer's protocol. Fibrinogen from bovine serum was dissolved to 2% (w/v) solution and polymerized with 50 U/ml thrombin Quantitative PCR Analysis to produce 500 µl volume aliquots of hydrogels. Hydro-Total RNA was isolated by lysing freshly pelleted cells gels were placed in sterile water, submerged in liquid by an RNAqueous isolation kit (Ambion #AM1912). nitrogen, freeze-dried using a lyophilizer (Labconco DNA contamination was enzymatically removed (Turbo 7740020), and sputtered-coated with 10 nm gold-palla-DNAse, Ambion) and 1 µg of total RNA was used to dium in a Denton Desktop-2 sputtering system. Samples build a cDNA library with the Reaction Ready cDNA were then mounted onto carbon tape and imaged in Hi-Synthesis kit (Superarray Bioscience Corporation) and a tachi 4700 Scanning Electron Microscope at a range of Biorad MyCycler according to the manufacturer's specimagnifications between 20 and 1000× and digitally stored.
fication. Custom RT2Profiler PCR Arrays (Superarray Bioscience Corporation, cat. #CAPH-0154B) were then Animal Model and Quantification of Retention run on a Stratagene MX-3005 cycler according to the Rowett (rnu/rnu) athymic nude rats (Harlan Spraguemanufacturer's protocol and analyzed with MxPro v3.0 Dawley) were used in studies approved by the Columbia software. Fold changes were expressed using the ∆∆Ct University Institutional Animal Care and Use Commitmethod with normalization of the raw data to the tee (IACUC). Rats were anesthetized with inhalation of GAPDH housekeeper. isoflurane (2-3%), endotracheally intubated, and mechanically ventilated. The heart was exposed through a Statistical Analysis left thoracotomy and the pericardium incised. The LAD was then ligated with 7-0 prolene suture 2-3 mm below All averages are reported as mean ± SD. For comparison between fibrin and saline suspended cells, a two-the edge of the left atrium. Confluent T75 flasks of fourth passage hMSCs were incubated overnight with 10 tailed Student's t-test was used with p < 0.05 considered significant. µl of iridium colloid label (Biopal, CL-300G02-1) prior
RESULTS
windows in the 6-8 min range could be achieved. Of note, fibrin glue preps crossing the 200 cP limit could be easily cleared from catheter C by manual flushing Given the importance of hydrogel flow properties for catheter-based delivery of cell/hydrogel suspensions, we with saline, enabling reuse of the catheter with freshly mixed fibrin glue. first specified the range of hydrogel viscosity that is compatible with the use of a catheter. Hydrogel prepara-To characterize the biocompatibility of fibrin glue, we encapsulated fourth passage mesenchymal stem cells tions were formed by utilizing dextran-based standards, to obtain a series of solutions with a gradually increasing in 2% w/v gels polymerized with 20 U/ml of thrombin. This preparation demonstrated excellent long-term via-viscosity. Four different catheter types with a wide range of path lengths (115-177.5 cm) and inner diameters bility ( Fig. 3a ) and normal morphology (Fig. 3b ) over 72 h of culture with hMSCs maintaining >90% viability (0.19-0.43 mm) were used in these rheological studies. Table 1 summarizes these studies. Dextran solutions at all time points. After 72 h, hydrogels were lyophilized for scanning electron microscopy (SEM), which demon-with concentrations less than 5% w/v (viscosity of ≤9.39 cP) were easily passed through all four catheters. All strated pore sizes in the 20-40 mm range (Fig. 3c ) and a somewhat homogenous architecture (Fig. 3d ). RT-PCR catheters except for the one with the longest and most narrow lumen (catheter D) handled the 10% dextran so-analysis of several hMSC markers including α-smooth muscle actin and connexin-43 showed no significant lution (viscosity of 30.8 cP) with ease. Injection of 20% dextran solutions (viscosity of 121 cP) was possible change in expression after 72 h of culture in fibrin glue (data not shown). through catheters A, B, and C, but significantly more force was required compared to less viscous solutions to
Having established acceptable parameters for percutaneous application, we tested the in vivo effective-produce forward flow. Only the catheter with the shortest path length (catheter C) was able to pass 25% dex-ness of intracardiac polymerization of fibrin glue in a rat model of acute myocardial infarction. Early at-tran solutions (231 cP). From these tests we estimated an operational viscosity upper limit in the 150-200 cP tempts to inject hydrogel via a 23-gauge needle resulted in excessive bleeding. After the needle size was range.
Next we analyzed the starting viscosity of fibrinogen reduced to 26 gauge 5/8 in., successful delivery of a 2% w/v fibrinogen/20 U/ml thrombin preparation was suspended in saline prior to addition of thrombin and initiation of polymerization ( Fig. 2a ). Fibrinogen solu-achieved with reproducible results. Intracardiac injection of this preparation resulted in a visible blanching tions demonstrated a nonlinear increase in viscosity; however, all solutions tested were well under the estab-of the anterior wall with no appreciable loss of injectate from the injection site (Fig. 4a ). Ten days postin-lished upper limit of 200 cP. Above fibrinogen concentrations of 15%, visible clumping occurred and could jection the anterior wall demonstrated visible retention of polymerized fibrin grossly (Fig. 4b, c ) and histolog-only be overcome by elevating the temperature of the mixture well above body temperature. Having now es-ically ( Fig. 4d) .
To quantify the effect of in situ polymerization of tablished acceptable starting concentrations of fibrinogen (<15% w/v) we characterized the time-dependent fibrin glue on cell retention and redistribution, we next suspended 500,000 iridium-labeled hMSCs in either sa-changes in viscosity associated with addition of thrombin and polymerization of fibrin monomers (Fig. 2b) . line or fibrin glue (2% w/v fibrinogen, 20 U/ml thrombin) and delivered them into acutely infarcted nude rats Early testing with higher fibrinogen concentrations (>10% w/v) was associated with rapid polymerization via two separate 150-µl injections. Ninety minutes after cell delivery, the rats were sacrificed and the hearts and that was incompatible with percutaneous delivery. In contrast, by decreasing the starting concentrations of fi-remote organs procured for quantification of retained cells (Fig. 4e ). There was no significant difference in brinogen to 5% and of thrombin to 20 U/ml, injection the total number of hMSCs recovered from the heart and DISCUSSION remote organs (3.31 ± 1.39 × 10 5 vs. 3.41 ± 1.00 × 10 5 , fibrin glue vs. saline). Delivery of hMSCs in fibrin glue Heart failure following acute and chronic myocardial infarction remains a therapeutic challenge with gradual was associated with a substantial increase in local cardiac retention (39.7 ± 7.0% vs. 22.6 ± 3.5% of recovered progression of disease and functional decline leading to death being the most common outcome. Various modal-cells, p < 0.05) as well as a significant reduction in redistribution to the liver (21.7 ± 7.9% vs. 41.7 ± 0.4%, ities of cell delivery have gained a lot of attention in recent years. While early clinical trial results were very p < 0.05) and kidney (0.3 ± 0.3% vs. 8.9 ± 8.8%, p < 0.05). Interestingly, redistribution of hMSCs to the lungs promising, larger randomized trials have produced conflicting data, sometimes with similar cell types showing was not statistically different for the two methods (38.3 ± 14.6% vs. 23.9 ± 9.3%).
sometimes positive and sometimes negative results. This lack of convincing evidence for the efficacy of delivered While some of the currently available catheters were suitable for cell/hydrogel delivery, a number of avenues cells may due to differences in cell processing, delivery methods, and timing of administration, such that poor for design improvement exists. First, given that the device with shortest path length and largest internal lumi-cell retention and engraftment remain a central problem common to all cell types and routes of administration.
nal diameter performed best, increasing the inner diameter even slightly may result in broadening the injection In this study, we have demonstrated that by controlling the composition of fibrinogen and thrombin compo-window by raising the upper limit of passable viscosity. Second, a double-lumen system that keeps the fibrinogen nents, a fibrin-based hydrogel can be prepared that is compatible with current percutaneous injection cathe-and thrombin components isolated until they reached the target tissue would potentially relieve the timing con-ters. This hydrogel can be delivered under clinically relevant conditions (point of care component mixing, straints associated with intracatheter polymerization altogether. 10-min injection window) and greatly enhances local retention of injected cells in the heart as well as prevents
As this was only an initial pilot study, more robust functional studies should be undertaken to determine if their redistribution to distance organs. Furthermore, the system and parameters developed here are applicable to the retention and distribution benefit demonstrated here results in greater functional recovery. The technique all cell types and may represent an enabling technology capable of improving current cell delivery techniques.
should also be applied to other cell types to confirm its 
